Vanguard Portfolio Management
FHTX icon

Vanguard Portfolio Management’s Foghorn Therapeutics FHTX Stock Holding History

Vanguard Portfolio Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
304,432
+48,501
+19% +$215K ﹤0.01% 2840
2026
Q1 		$1.22M Buy
+255,931
New +$1.41M ﹤0.01% 2738

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Portfolio Management's FHTX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Foghorn Therapeutics (FHTX) stake by 19% in Q2 2026, buying an estimated $215K and bringing the position to 304,432 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

Vanguard Portfolio Management first reported a position in FHTX in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Vanguard Portfolio Management held 304,432 shares of Foghorn Therapeutics worth $1.49M as of Q2 2026.
  • Vanguard Portfolio Management bought 48,501 Foghorn Therapeutics shares in Q2 2026, an estimated $215K.
  • Foghorn Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2840 holding.
  • Vanguard Portfolio Management first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.